Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 78/100

Tandem Diabetes Care Inc at UBS Global Healthcare Conference Transcript

May 20, 2019 / 07:30PM GMT
Release Date Price: €58.98 (-6.26%)
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

All right. So thanks everybody for joining us for this session. I'm really pleased to be joined by management from Tandem, including John Sheridan, who's the President and CEO. And he's been that since March 2019, previously serving as EVP and COO since April 2013. I'm also joined by Leigh Vosseller, who's the EVP and CFO, who joined as the CFO effective January 1, 2018, and previously had served as SVP of Finance since August 2017.

Questions & Answers

Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

So I think to start we would just like to -- allow you to just make some opening comments, we'll talk about growth here, but I'd like to give you the opportunity to talk a little bit about the state of the union, with such strong growth that you've seen over the last year, the introduction of a great combination product. Can you talk a little bit about that, how

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot